China Southern Fund's Hong Kong Connect Innovative Drug ETF has attracted significant attention from investors, with a concentrated release of favorable news for innovative drugs. Short-term corrections do not change its long-term allocation value

As of March 9, 2026, the Hong Kong Stock Connect Innovative Drug ETF China Southern (159297) had a turnover of 6.69%, with a transaction volume of 105 million yuan, while the tracked CNI Hong Kong Connect Innovative Drug Index fell by 1.7%. Soochow Securities pointed out that the Two Sessions have for the first time listed innovative drugs as an "emerging pillar industry" and proposed to accelerate the development of commercial insurance to promote the high-quality development of innovative drugs. The biopharmaceutical industry has entered a strategic pillar stage, and the medium- to long-term allocation value of the innovative drug sector has attracted attention, making it a good time for investment